510(k) K062028

CYSTIC FIBROSIS GENOTYPING ASSAY, MODEL 6L20-01 by Celera Diagnostics — Product Code NUA

K062028 is an FDA 510(k) premarket notification submitted by Celera Diagnostics for the device "CYSTIC FIBROSIS GENOTYPING ASSAY, MODEL 6L20-01". The FDA issued a decision of Substantially Equivalent on Sep 7, 2007. The device falls under product code NUA (System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection), a Class II device regulated under 21 CFR 866.5900.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Sep 7, 2007
Date Received
Jul 18, 2006
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection
Device Class
Class II
Regulation Number
866.5900
Review Panel
PA
Submission Type
510(k)

The cftr gene mutation detection system is a device used to simultaneously detect and identify a panel of mutations and variants in the cftr gene. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (cf), carrier identification, and newborn screening. This device is not intended for stand-alone diagnostic purposes, prenatal diagnostic, pre-implantation or population screening.

Need the full FDA record for Celera Diagnostics? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K062028. Report a data issue: hello@regdatalab.com.